Jane also picked up another 10K shares bringing her total to roughly 26.5 Million. Three insiders buying this month,, Jane, Rubin and the other guy, um what's his name.
Thom, the last sentence from the above passage reads :
" We plan to use the Inspiromatic™ device to test the inhaled form of OPKO's new sulfated disaccharide drug against these disorders."
This is interesting because Opko can license out the inhaler which could be big, or move to a phase 1-2-3 with their in house product which could prove to be the best asthma drug on the market. Not necessarily because the drug is in fact superior, but because of a far superior delivery system.
Love to be at OPKO head quarters to hear that debate.
Yahoo letting me use ignore feature, YAHOO
cashed in several options, covered taxes, increasing his LONG position to 4.478M.
these phase studies are expensive. 4k roll out will likely be like a small snowball rolling down a mountain, revenue will be slow but double q over q for a few years. This new inhaler and the phase studies to follow come at a great time because two expensive studies have or will end shortly. R and D expense should drop dramatically even with the new yet to be announced study.
The net result was he bought 208,411 shares, used the shares sold to pay taxes, and help buy the 208k shares, go buy a clue.
Paper work was put in with the fda back in 2012 to do a phase 1-2 study of the device based on the identical format used in the Israel study, but the fda site says not yet recruiting. Think this item can move fast for approval because it uses a similar but not identical device that is on the market as standard care. Basically needs only show equal drug delivery, but in the Israeli study it already proved superior. Enrollment should be quick, measuring drug uptake is easy, study could be completed in under six months for the device. With a NEW DRUG however it might take the normal couple years, but for the device itself, months. Good job Dr. Frost, this could be the next new standard inhaler one that could be licensed to many companies, or kept as proprietary.
In May 2013, Inspiro successfully concluded an FIM study in which both primary and secondary endpoints were met. Statistically, the Inspiromatic™ performed significantly better than the market gold standard inhaler. (This study served as confirmation of the successful in vitro studies Inspiro Medical conducted in July 2012, which clearly demonstrated Inspiromatic’s cutting-edge technology for improved drug deposition in the lung.)
The aim of the FIM study, which was conducted at Schneider Children’s Medical Center, in Petach Tikva, Israel, was to objectively assess the efficacy and safety profiles of bronchodilator treatment via Inspiromatic™ in 30 asthmatic children, as compared to its delivery via a gold-standard inhaler.
The results demonstrated superior performance by Inspiromatic in pulmonary delivery of the active drug.
Lung function test (FEV1) demonstrated a statistically significant improvement following drug delivery via the Inspiromatic.
Successful delivery of the API was achieved on patients with poor inhalation technique and even those with a low-flow inhalation rate.
Patients rated Inspiromatic very high.
Inspiro Medical has developed a novel dry powder drug delivery solution for pulmonary indications. Inspiro’s Inspiromatic can be programmed to achieve maximum effectiveness by delivering the prescribed amount of drugs to a targeted spot on the lungs. This is accomplished by a flow sensor embedded into the hand-held Inspiromatic taking into account the patient’s inhalation flow rates and breathing patterns as well as an active particle’s de-agglomeration mechanism.
During ill patient simulations, Inspiro delivered twice the amount of drugs compared with competing inhalers. With Inspiro Medical, even children, the elderly and the seriously ill can benefit by enhanced dry powder drug delivery without forceful inhalation.
The Inspiromatic is a sleek hand-held device that is cost effective in the sense that the drug formulation does not remain in the loading chamber. Also, a built-in data logger indicates whether or not a proper inhalation technique has been adhered to, which is crucial in ensuring that the appropriate amount of drugs are released. Finally, direct communications between the Inspiromatic and the physician is facilitated by USB and wireless connectivity.
The buyer can with written notice ( 61 days ) increase ownership up to 9.99% of shares outstanding. So basically you reported half of the paragraph. So basically you have guessed at what the individual might have done, but reality is you have NO idea.
From the filing.
The “Beneficial Ownership Limitation” shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon not less than 61 days’ prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply
So basically the buyer needs sell no shares to exercise the warrants, and actually could be a buyer in the open market TODAY without impacting the warrants.
You present info the same way AF does, distorted to suit your agenda.
Adsmith, have you looked at exel, I do not own it, but crushed from 7's to about 3.50, has 4 phase 3 studies, and partner structure similar to arry. I am not in a position to add any more positions today but exel is interesting and one I might nibble on. Currently I have 3 spec stocks so that is maxed out.
In the prior two cash raises warrants were issued and can be bought and sold on the exchange. NWBO did the right thing to note there was not going to be warrant dilution. There is a significant difference between a warrant and and option.
Think again, what he said is NWBO does not have to worry about the stock tanking because they are now financed. So now if NWBO announced bad news and it tanks no problem, they got their 15 million on hand.
AF will not say one positive about nwbo, let alone it won't tank.
Shorts own the right to buy shares and support share price. Nothing more, nothing less. Positive news they exercise their right at at a higher loss, negative news break even.
The asco move usually starts end of April. Just buy and wait.
Oliver, U do know PEI saw every bit of data including any compassionate use, BUT no phase 3 data according to Linda Powers. So no reason my not so flowery PEI reco is not valid if they KNEW they could KILL two alternate hospitals if they thought they were frauds, just throwing a possibility out there.
I mean the American GOV would never make a dubious move like this, approve company a to kill company b, FOREVER. A possibility none the less.
Market it means just that. No TV ads, no posters, bulletin boards, no radio ads, no magazine ads. The Dr. has to mention the option, or if not, as a patient you can request it. If the Dr. is unaware or the patient is unaware of the option, they will never discover it in the media.
6 hospitals can offer it if the Dr. thinks it a good idea. It is a given that if Drs. are aware it gets offered. The treatment causes no harm, so if it does not work the patient LOST nothing. If it does work the patient might live 2-3 extra years, or even be cured. A win cannot lose situation.